Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$328.8K
Program Spending
100%
of total expenses go to program services
Total Contributions
$328.8K
Total Expenses
▼$300.7K
Total Assets
$31K
Total Liabilities
▼$0
Net Assets
$31K
Officer Compensation
→$89.7K
Other Salaries
$3,622
Investment Income
$0
Fundraising
▼$0
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$7.4M
VA/DoD Award Count
6
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$34.2M
Awards Found
29
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | HEALTH CENTER CLUSTER | $8.6M | FY2002 | Feb 2002 – Dec 2016 |
| Department of Health and Human Services | LONG-ACTING PTH FOR HYPOPARATHYROIDISM | $6.7M | FY2015 | Sep 2015 – May 2023 |
| VA/DoDDepartment of Veterans Affairs | VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS. | $4.3M | — | — – — |
| Department of Health and Human Services | LONG-ACTING GHRELIN FOR THE TREATMENT OF CANCER CACHEXIA | $2.2M | FY2017 | Apr 2017 – Mar 2020 |
| Department of Health and Human Services | LONG-ACTING PTH FOR HYPOPARATHYROIDISM - PROJECT SUMMARY HYPOPARATHYROIDISM IS A RARE DISEASE THAT RESULTS FROM A DEFICIENCY OR INABILITY TO MAKE SUFFICIENT AMOUNTS OF PARATHYROID HORMONE (PTH). UNTREATED OR INADEQUATELY TREATED HYPOPARATHYROIDISM LEADS TO CLINICALLY SIGNIFICANT MINERAL-RELATED METABOLIC ISSUES INCLUDING HYPOCALCEMIA, WHICH LEADS TO HEART ARRHYTHMIAS, SPASMS OF THE VOCAL CORDS, AND SEIZURES. CURRENT MANAGEMENT OF THE DISEASE FOR THE MAJORITY OF PATIENTS CONSISTS OF SUPPLEMENTAL DOSES OF CALCIUM AND ACTIVE VITAMIN D TO MANAGE THE HYPOCALCEMIA. WHILE THIS APPROACH IS INTENDED TO MAINTAIN SERUM CALCIUM, IT DOES NOT CORRECT THE UNDERLYING PTH DEFICIENCY AND THE PHYSIOLOGICAL ASPECTS OF HYPOPARATHYROIDISM CAN STILL OCCUR. MOREOVER, SUPPLEMENTATION IS ASSOCIATED WITH LONG-TERM COMPLICATIONS FROM THE USE OF SUPRAPHYSIOLOGICAL DOSES OF CALCIUM IN THE ABSENCE OF ENDOGENOUS PTH HORMONE, WHICH CONTRIBUTE TO RENAL FUNCTION DETERIORATION, KIDNEY STONES, SOFT TISSUE CALCIFICATIONS AND ABNORMALITIES IN BONE REMODELING. NATPARA (PTH 1-84), IS APPROVED BY THE FDA FOR A SUBSET OF HYPOPARATHYROIDISM PATIENTS, BUT ONLY PARTIALLY ALLEVIATES THE NEED FOR VITAMIN SUPPLEMENTATION DUE TO ITS SHORT HALF-LIFE, AND SOME PATIENTS STILL MUST TAKE >10 PILLS/DAY. CLINICAL TRIALS HAVE DEMONSTRATED THAT IF PTH(1-34) IS DOSED CONTINUOUSLY VIA A PUMP IN HUMANS, IT CAN MIMIC PHYSIOLOGICAL LEVELS OF PTH TO RESTORE NORMAL LEVELS OF CALCIUM, PHOSPHORUS AND MARKERS OF BONE TURNOVER. HOWEVER, A PUMP-MEDIATED, CONTINUOUS INFUSION OF PTH WOULD BE COSTLY AND INCONVENIENT FOR PATIENTS. EXTEND BIOSCIENCES HAS DEVELOPED A LONG-ACTING VERSION OF PTH(1-34) (EXT608) THAT COULD BE DOSED ONCE A WEEK AND ACHIEVE A PROLONGED PHARMACOKINETIC PROFILE THAT APPROXIMATES ENDOGENOUS PTH LEVELS. SBIR PHASE II RESULTS SHOWED THAT EXT608 IS MORE EFFICACIOUS THAN NATIVE PTH, AND BASED ON THE RETENTION TIME IN RAT AND NHP, EXT608 IS PROJECTED TO BE DOSED ONCE-WEEKLY IN HUMANS. IN OUR ONGOING PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS, THE DRUG HAS BEEN WELL TOLERATED WITH NO ADVERSE EVENTS. THE STUDIES PROPOSED IN THIS DIRECT TO PHASE II APPLICATION WILL FOCUS ON A SECOND CLINICAL STUDY IN HEALTHY VOLUNTEERS LOOKING AT THE EFFECT OF MULTIPLE DOSES. WE WILL BEGIN A PHASE 2 CLINICAL TRIAL TO DETERMINE SAFETY AND TOLERABILITY OF EXT608 IN PATIENTS FOLLOWING THIS STUDY. THIS LONG-ACTING PTH(1-34) DERIVATIVE WILL PROVIDES A TRUE REPLACEMENT THERAPY TO TREAT HYPOPARATHYROIDISM THAT RETURNS SERUM AND URINARY CALCIUM AND PHOSPHATE TO PHYSIOLOGICAL LEVELS THAT WILL SIGNIFICANTLY IMPROVE THE QUALITY OF LIFE FOR PATIENTS. | $2M | FY2024 | Sep 2024 – Aug 2026 |
| Department of Health and Human Services | A PHASE 2 STUDY INVESTIGATING THE SAFETY, TOLERABILITY AND EFFICACY OF EXT608 IN ADULTS WITH HYPOPARATHYROIDISM (IND146180; OCTOBER 14, 2022) - PROJECT SUMMARY HYPOPARATHYROIDISM IS A RARE DISEASE THAT RESULTS FROM A DEFICIENCY OR INABILITY TO MAKE SUFFICIENT AMOUNTS OF PARATHYROID HORMONE (PTH). UNTREATED OR INADEQUATELY TREATED HYPOPARATHYROIDISM LEADS TO CLINICALLY SIGNIFICANT MINERAL-RELATED METABOLIC ISSUES INCLUDING HYPOCALCEMIA, WHICH LEADS TO HEART ARRHYTHMIAS, SPASMS OF THE VOCAL CORDS, AND SEIZURES. CURRENT MANAGEMENT OF THE DISEASE FOR THE MAJORITY OF PATIENTS CONSISTS OF SUPPLEMENTAL DOSES OF CALCIUM AND ACTIVE VITAMIN D TO MANAGE THE HYPOCALCEMIA. WHILE THIS APPROACH IS INTENDED TO MAINTAIN SERUM CALCIUM, IT DOES NOT CORRECT THE UNDERLYING PTH DEFICIENCY AND THE PHYSIOLOGICAL ASPECTS OF HYPOPARATHYROIDISM CAN STILL OCCUR. MOREOVER, SUPPLEMENTATION IS ASSOCIATED WITH LONG-TERM COMPLICATIONS FROM THE USE OF SUPRAPHYSIOLOGICAL DOSES OF CALCIUM IN THE ABSENCE OF ENDOGENOUS PTH HORMONE, WHICH CONTRIBUTE TO RENAL FUNCTION DETERIORATION, KIDNEY STONES, SOFT TISSUE CALCIFICATIONS AND ABNORMALITIES IN BONE REMODELING. NATPARA (PTH 1-84), WAS APPROVED BY THE FDA FOR A SUBSET OF HYPOPARATHYROIDISM PATIENTS, BUT ONLY PARTIALLY ALLEVIATES THE NEED FOR VITAMIN SUPPLEMENTATION DUE TO ITS SHORT HALF-LIFE, AND IT WAS RECENTLY ANNOUNCED THAT MANUFACTURING WILL CEASE IN 2024. CLINICAL TRIALS HAVE DEMONSTRATED THAT IF PTH(1-34) IS DOSED CONTINUOUSLY VIA A PUMP IN HUMANS, IT CAN MIMIC PHYSIOLOGICAL LEVELS OF PTH TO RESTORE NORMAL LEVELS OF CALCIUM, PHOSPHORUS AND MARKERS OF BONE TURNOVER. HOWEVER, A PUMP-MEDIATED, CONTINUOUS INFUSION OF PTH WOULD BE COSTLY AND INCONVENIENT FOR PATIENTS. EXTEND BIOSCIENCES HAS DEVELOPED A LONG-ACTING VERSION OF PTH(1-34) (EXT608) THAT ACHIEVES A PROLONGED PHARMACOKINETIC PROFILE THAT APPROXIMATES ENDOGENOUS PTH LEVELS. BASED ON AN INTERIM DATA ANALYSIS OF PHASE 1 RESULTS PRIOR TO DATABASE LOCK, EXT608 WAS SAFE AND WELL-TOLERATED AND IS PROJECTED TO BE DOSED ONCE-WEEKLY IN HUMANS. THE STUDIES PROPOSED IN THIS GRANT APPLICATION WILL FOCUS ON A PHASE 2 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL IN PATIENTS. THIS TRIAL WILL HELP DEMONSTRATE THAT THIS LONG-ACTING PTH(1-34) DERIVATIVE IS PROVIDES A SUPERIOR PTH BASED THERAPY TO TREAT HYPOPARATHYROIDISM THAT RETURNS SERUM AND URINARY CALCIUM AND PHOSPHATE TO PHYSIOLOGICAL LEVELS AND MAINTAINS IT OVER THE COURSE OF WEEK, THEREBY SIGNIFICANTLY IMPROVING COMPLIANCE AND QUALITY OF LIFE FOR PATIENTS. | $1.8M | FY2023 | Sep 2023 – Feb 2028 |
| VA/DoDDepartment of Veterans Affairs | VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS. | $1.6M | — | — – — |
| National Science Foundation | SBIR PHASE II: A PLATFORM TECHNOLOGY THAT SIGNIFICANTLY IMPROVES DRUG DELIVERY | $908K | FY2015 | Nov 2014 – Apr 2018 |
| VA/DoDDepartment of Veterans Affairs | VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS. | $819.9K | — | — – — |
| VA/DoDDepartment of Veterans Affairs | VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS. | $647.3K | — | — – — |
| Department of Health and Human Services | LONG-ACTING GHRELIN FOR THE TREATMENT OF ARS | $600K | FY2017 | Mar 2017 – Feb 2019 |
| Department of Health and Human Services | LONG-ACTING GHRELIN FOR NEUROPATHY | $535.3K | FY2019 | Sep 2019 – Aug 2021 |
| Department of Health and Human Services | RURAL HEALTH CARE SERVICES OUTREACH GRANT PROGRAM | $530K | FY2015 | May 2015 – Apr 2018 |
| Department of Health and Human Services | A SYSTEMICALLY DELIVERABLE RNAI-BASED APPROACH FOR ALCOHOLIC LIVER DISEASE | $445.1K | FY2013 | Sep 2013 – Aug 2016 |
| Department of Health and Human Services | ARRA - CAPITAL IMPROVEMENT PROGRAM | $417.3K | FY2009 | Jun 2009 – Jun 2011 |
| Department of Health and Human Services | ULTRALONG-ACTING INSULIN FOR DIABETES | $350K | FY2017 | Sep 2017 – Sep 2019 |
| Department of Justice | ACCESS TRANSITIONAL HOUSING PROGRAM | $340.1K | FY2016 | Oct 2015 – Dec 2018 |
| Department of Health and Human Services | LONG ACTING PTH FOR HYPOPARATHYROIDISM | $306.7K | FY2015 | Sep 2015 – Aug 2016 |
| Department of Health and Human Services | LONG LASTING GHRELIN DERIVATIVES FOR THE TREATMENT OF CANCER CACHEXIA | $288.3K | FY2013 | May 2013 – Apr 2015 |
| National Science Foundation | SBIR PHASE I: DEVELOPMENT OF A PLATFORM FOR RAPID "PLUG AND PLAY" CHEMO-ENZYMATIC CONJUGATION OF BIO-THERAPEUTICS | $179.3K | FY2014 | Jan 2014 – Dec 2014 |
| Department of Health and Human Services | ARRA - INCREASE SERVICES TO HEALTH CENTERS | $157.5K | FY2009 | Mar 2009 – Mar 2011 |
| National Science Foundation | SBIR PHASE I: CARRIERS FOR IMPROVED DRUG DELIVERY OF BIOPHARMACEUTICALS | $150K | FY2013 | Jan 2013 – Jun 2013 |
| Department of Health and Human Services | AFFORDABLE CARE ACT (ACA) GRANTS FOR SCHOOL-BASED HEALTH CENTERS CAPITAL PROGRAM | $136.3K | FY2011 | Jul 2011 – Jun 2013 |
| VA/DoDDepartment of Veterans Affairs | VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS. | $58.7K | — | — – — |
| Department of Agriculture | REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT | $52.8K | FY2023 | Aug 2023 – Aug 2025 |
| VA/DoDDepartment of Veterans Affairs | VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS. | $42.3K | — | — – — |
| Department of Agriculture | DIRECT COMMUNITY FACILITY LOANS | $22K | FY2008 | Dec 2007 – Dec 2007 |
| Department of Health and Human Services | RURAL HEALTH CLINIC VACCINE CONFIDENCE PROGRAM | $0 | FY2021 | Jul 2021 – Dec 2022 |
| Department of Health and Human Services | RURAL HEALTH CARE SERVICES OUTREACH GRANT PROGRAM | -$6 | FY2015 | May 2015 – Apr 2018 |
Department of Health and Human Services
$8.6M
HEALTH CENTER CLUSTER
Department of Health and Human Services
$6.7M
LONG-ACTING PTH FOR HYPOPARATHYROIDISM
Department of Veterans Affairs
$4.3M
VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.
Department of Health and Human Services
$2.2M
LONG-ACTING GHRELIN FOR THE TREATMENT OF CANCER CACHEXIA
Department of Health and Human Services
$2M
LONG-ACTING PTH FOR HYPOPARATHYROIDISM - PROJECT SUMMARY HYPOPARATHYROIDISM IS A RARE DISEASE THAT RESULTS FROM A DEFICIENCY OR INABILITY TO MAKE SUFFICIENT AMOUNTS OF PARATHYROID HORMONE (PTH). UNTREATED OR INADEQUATELY TREATED HYPOPARATHYROIDISM LEADS TO CLINICALLY SIGNIFICANT MINERAL-RELATED METABOLIC ISSUES INCLUDING HYPOCALCEMIA, WHICH LEADS TO HEART ARRHYTHMIAS, SPASMS OF THE VOCAL CORDS, AND SEIZURES. CURRENT MANAGEMENT OF THE DISEASE FOR THE MAJORITY OF PATIENTS CONSISTS OF SUPPLEMENTAL DOSES OF CALCIUM AND ACTIVE VITAMIN D TO MANAGE THE HYPOCALCEMIA. WHILE THIS APPROACH IS INTENDED TO MAINTAIN SERUM CALCIUM, IT DOES NOT CORRECT THE UNDERLYING PTH DEFICIENCY AND THE PHYSIOLOGICAL ASPECTS OF HYPOPARATHYROIDISM CAN STILL OCCUR. MOREOVER, SUPPLEMENTATION IS ASSOCIATED WITH LONG-TERM COMPLICATIONS FROM THE USE OF SUPRAPHYSIOLOGICAL DOSES OF CALCIUM IN THE ABSENCE OF ENDOGENOUS PTH HORMONE, WHICH CONTRIBUTE TO RENAL FUNCTION DETERIORATION, KIDNEY STONES, SOFT TISSUE CALCIFICATIONS AND ABNORMALITIES IN BONE REMODELING. NATPARA (PTH 1-84), IS APPROVED BY THE FDA FOR A SUBSET OF HYPOPARATHYROIDISM PATIENTS, BUT ONLY PARTIALLY ALLEVIATES THE NEED FOR VITAMIN SUPPLEMENTATION DUE TO ITS SHORT HALF-LIFE, AND SOME PATIENTS STILL MUST TAKE >10 PILLS/DAY. CLINICAL TRIALS HAVE DEMONSTRATED THAT IF PTH(1-34) IS DOSED CONTINUOUSLY VIA A PUMP IN HUMANS, IT CAN MIMIC PHYSIOLOGICAL LEVELS OF PTH TO RESTORE NORMAL LEVELS OF CALCIUM, PHOSPHORUS AND MARKERS OF BONE TURNOVER. HOWEVER, A PUMP-MEDIATED, CONTINUOUS INFUSION OF PTH WOULD BE COSTLY AND INCONVENIENT FOR PATIENTS. EXTEND BIOSCIENCES HAS DEVELOPED A LONG-ACTING VERSION OF PTH(1-34) (EXT608) THAT COULD BE DOSED ONCE A WEEK AND ACHIEVE A PROLONGED PHARMACOKINETIC PROFILE THAT APPROXIMATES ENDOGENOUS PTH LEVELS. SBIR PHASE II RESULTS SHOWED THAT EXT608 IS MORE EFFICACIOUS THAN NATIVE PTH, AND BASED ON THE RETENTION TIME IN RAT AND NHP, EXT608 IS PROJECTED TO BE DOSED ONCE-WEEKLY IN HUMANS. IN OUR ONGOING PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS, THE DRUG HAS BEEN WELL TOLERATED WITH NO ADVERSE EVENTS. THE STUDIES PROPOSED IN THIS DIRECT TO PHASE II APPLICATION WILL FOCUS ON A SECOND CLINICAL STUDY IN HEALTHY VOLUNTEERS LOOKING AT THE EFFECT OF MULTIPLE DOSES. WE WILL BEGIN A PHASE 2 CLINICAL TRIAL TO DETERMINE SAFETY AND TOLERABILITY OF EXT608 IN PATIENTS FOLLOWING THIS STUDY. THIS LONG-ACTING PTH(1-34) DERIVATIVE WILL PROVIDES A TRUE REPLACEMENT THERAPY TO TREAT HYPOPARATHYROIDISM THAT RETURNS SERUM AND URINARY CALCIUM AND PHOSPHATE TO PHYSIOLOGICAL LEVELS THAT WILL SIGNIFICANTLY IMPROVE THE QUALITY OF LIFE FOR PATIENTS.
Department of Health and Human Services
$1.8M
A PHASE 2 STUDY INVESTIGATING THE SAFETY, TOLERABILITY AND EFFICACY OF EXT608 IN ADULTS WITH HYPOPARATHYROIDISM (IND146180; OCTOBER 14, 2022) - PROJECT SUMMARY HYPOPARATHYROIDISM IS A RARE DISEASE THAT RESULTS FROM A DEFICIENCY OR INABILITY TO MAKE SUFFICIENT AMOUNTS OF PARATHYROID HORMONE (PTH). UNTREATED OR INADEQUATELY TREATED HYPOPARATHYROIDISM LEADS TO CLINICALLY SIGNIFICANT MINERAL-RELATED METABOLIC ISSUES INCLUDING HYPOCALCEMIA, WHICH LEADS TO HEART ARRHYTHMIAS, SPASMS OF THE VOCAL CORDS, AND SEIZURES. CURRENT MANAGEMENT OF THE DISEASE FOR THE MAJORITY OF PATIENTS CONSISTS OF SUPPLEMENTAL DOSES OF CALCIUM AND ACTIVE VITAMIN D TO MANAGE THE HYPOCALCEMIA. WHILE THIS APPROACH IS INTENDED TO MAINTAIN SERUM CALCIUM, IT DOES NOT CORRECT THE UNDERLYING PTH DEFICIENCY AND THE PHYSIOLOGICAL ASPECTS OF HYPOPARATHYROIDISM CAN STILL OCCUR. MOREOVER, SUPPLEMENTATION IS ASSOCIATED WITH LONG-TERM COMPLICATIONS FROM THE USE OF SUPRAPHYSIOLOGICAL DOSES OF CALCIUM IN THE ABSENCE OF ENDOGENOUS PTH HORMONE, WHICH CONTRIBUTE TO RENAL FUNCTION DETERIORATION, KIDNEY STONES, SOFT TISSUE CALCIFICATIONS AND ABNORMALITIES IN BONE REMODELING. NATPARA (PTH 1-84), WAS APPROVED BY THE FDA FOR A SUBSET OF HYPOPARATHYROIDISM PATIENTS, BUT ONLY PARTIALLY ALLEVIATES THE NEED FOR VITAMIN SUPPLEMENTATION DUE TO ITS SHORT HALF-LIFE, AND IT WAS RECENTLY ANNOUNCED THAT MANUFACTURING WILL CEASE IN 2024. CLINICAL TRIALS HAVE DEMONSTRATED THAT IF PTH(1-34) IS DOSED CONTINUOUSLY VIA A PUMP IN HUMANS, IT CAN MIMIC PHYSIOLOGICAL LEVELS OF PTH TO RESTORE NORMAL LEVELS OF CALCIUM, PHOSPHORUS AND MARKERS OF BONE TURNOVER. HOWEVER, A PUMP-MEDIATED, CONTINUOUS INFUSION OF PTH WOULD BE COSTLY AND INCONVENIENT FOR PATIENTS. EXTEND BIOSCIENCES HAS DEVELOPED A LONG-ACTING VERSION OF PTH(1-34) (EXT608) THAT ACHIEVES A PROLONGED PHARMACOKINETIC PROFILE THAT APPROXIMATES ENDOGENOUS PTH LEVELS. BASED ON AN INTERIM DATA ANALYSIS OF PHASE 1 RESULTS PRIOR TO DATABASE LOCK, EXT608 WAS SAFE AND WELL-TOLERATED AND IS PROJECTED TO BE DOSED ONCE-WEEKLY IN HUMANS. THE STUDIES PROPOSED IN THIS GRANT APPLICATION WILL FOCUS ON A PHASE 2 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL IN PATIENTS. THIS TRIAL WILL HELP DEMONSTRATE THAT THIS LONG-ACTING PTH(1-34) DERIVATIVE IS PROVIDES A SUPERIOR PTH BASED THERAPY TO TREAT HYPOPARATHYROIDISM THAT RETURNS SERUM AND URINARY CALCIUM AND PHOSPHATE TO PHYSIOLOGICAL LEVELS AND MAINTAINS IT OVER THE COURSE OF WEEK, THEREBY SIGNIFICANTLY IMPROVING COMPLIANCE AND QUALITY OF LIFE FOR PATIENTS.
Department of Veterans Affairs
$1.6M
VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.
National Science Foundation
$908K
SBIR PHASE II: A PLATFORM TECHNOLOGY THAT SIGNIFICANTLY IMPROVES DRUG DELIVERY
Department of Veterans Affairs
$819.9K
VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.
Department of Veterans Affairs
$647.3K
VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.
Department of Health and Human Services
$600K
LONG-ACTING GHRELIN FOR THE TREATMENT OF ARS
Department of Health and Human Services
$535.3K
LONG-ACTING GHRELIN FOR NEUROPATHY
Department of Health and Human Services
$530K
RURAL HEALTH CARE SERVICES OUTREACH GRANT PROGRAM
Department of Health and Human Services
$445.1K
A SYSTEMICALLY DELIVERABLE RNAI-BASED APPROACH FOR ALCOHOLIC LIVER DISEASE
Department of Health and Human Services
$417.3K
ARRA - CAPITAL IMPROVEMENT PROGRAM
Department of Health and Human Services
$350K
ULTRALONG-ACTING INSULIN FOR DIABETES
Department of Justice
$340.1K
ACCESS TRANSITIONAL HOUSING PROGRAM
Department of Health and Human Services
$306.7K
LONG ACTING PTH FOR HYPOPARATHYROIDISM
Department of Health and Human Services
$288.3K
LONG LASTING GHRELIN DERIVATIVES FOR THE TREATMENT OF CANCER CACHEXIA
National Science Foundation
$179.3K
SBIR PHASE I: DEVELOPMENT OF A PLATFORM FOR RAPID "PLUG AND PLAY" CHEMO-ENZYMATIC CONJUGATION OF BIO-THERAPEUTICS
Department of Health and Human Services
$157.5K
ARRA - INCREASE SERVICES TO HEALTH CENTERS
National Science Foundation
$150K
SBIR PHASE I: CARRIERS FOR IMPROVED DRUG DELIVERY OF BIOPHARMACEUTICALS
Department of Health and Human Services
$136.3K
AFFORDABLE CARE ACT (ACA) GRANTS FOR SCHOOL-BASED HEALTH CENTERS CAPITAL PROGRAM
Department of Veterans Affairs
$58.7K
VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.
Department of Agriculture
$52.8K
REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT
Department of Veterans Affairs
$42.3K
VA IS PROVIDING PER DIEM FUNDING TO ASSIST WITH THE OPERATIONAL COSTS ASSOCIATED WITH TRANSITIONAL HOUSING BEDS FOR HOMELESS VETERANS.
Department of Agriculture
$22K
DIRECT COMMUNITY FACILITY LOANS
Department of Health and Human Services
$0
RURAL HEALTH CLINIC VACCINE CONFIDENCE PROGRAM
Department of Health and Human Services
-$6
RURAL HEALTH CARE SERVICES OUTREACH GRANT PROGRAM
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2024 · Source: IRS e-Filed Form 990
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
WarningTax-exempt status was revoked on May 15, 2023
Reinstated on November 15, 2023
Exemption type: 03
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $328.8K | $328.8K | $300.7K | $31K | $31K |
| 2019 | $126.8K | — | $0 | $2,114 | — |
| 2018 | $90.6K | — | $89.8K | $8,789 | — |
| 2017 | $35.3K | — | $1,253 |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2019 | 990-EZ | Data | |
| 2018 | 990-EZ | Data |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
Revocation status: IRS Auto-Revocation List
| Total |
|---|
| Sam Sussman | Director | 50 | $85.5K | $0 | $0 | $85.5K |
| Benzi Sanders | Jerusalem Program Director | 40 | $4,209 | $0 | $0 | $4,209 |
Sam Sussman
Director
$85.5K
Hrs/Wk
50
Compensation
$85.5K
Related Orgs
$0
Other
$0
Benzi Sanders
Jerusalem Program Director
$4,209
Hrs/Wk
40
Compensation
$4,209
Related Orgs
$0
Other
$0
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Elliot Ratzman | Board Member | 1 | $0 | $0 | $0 | $0 |
| Jai Retter | Board Member | 1 | $0 | $0 | $0 | $0 |
| Judy Roth | Board Member | 1 | $0 | $0 | $0 | $0 |
| Moss Raz | Board Member | 1 | $0 | $0 | $0 | $0 |
| Steve Ross | Board Member | 1 | $0 | $0 | $0 | $0 |
Elliot Ratzman
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Jai Retter
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Judy Roth
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
| $7,996 |
| — |
| 2016 | $30.9K | — | $25.6K | $6,743 | — |
| 2015 | $18.3K | — | $18.9K | $1,430 | — |
| 2017 | 990-EZ | Data |
| 2016 | 990-EZ | Data |
| 2015 | 990-EZ | Data |
Moss Raz
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0
Steve Ross
Board Member
$0
Hrs/Wk
1
Compensation
$0
Related Orgs
$0
Other
$0